STOCK TITAN

[8-K] Lantern Pharma Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Sprinklr, Inc. (CXM) – Form 144 filing dated 07/29/2025

Insider Ragy Thomas has filed a Form 144 indicating an intent to sell 1,435 common shares on or about 29 Jul 2025 through Morgan Stanley Smith Barney. At the 07/28/2025 closing price, the shares are valued at $13,429.73. The company has 142,831,141 shares outstanding; the proposed sale represents <0.01 % of shares outstanding and is therefore immaterial in size.

The filing also discloses recent insider activity: over the prior three months Thomas sold an aggregate 9,327,768 shares in four transactions, generating gross proceeds of roughly $73.1 million. These larger prior sales amount to about 6.5 % of the shares outstanding and may signal continued divestiture by a key insider.

Because Form 144 is only a notice of intent, execution is not guaranteed. Nonetheless, recurring sizable sales by a founder/executive can influence market sentiment, especially if not paired with offsetting purchases or public rationale.

Sprinklr, Inc. (CXM) – Comunicazione Form 144 datata 29/07/2025

L'insider Ragy Thomas ha presentato un modulo Form 144 indicando l'intenzione di vendere 1.435 azioni ordinarie intorno al 29 luglio 2025 tramite Morgan Stanley Smith Barney. Al prezzo di chiusura del 28/07/2025, le azioni valgono 13.429,73 $. La società conta 142.831.141 azioni in circolazione; la vendita proposta rappresenta quindi meno dello 0,01 % delle azioni totali ed è pertanto di entità trascurabile.

La comunicazione rivela anche una recente attività degli insider: negli ultimi tre mesi Thomas ha venduto complessivamente 9.327.768 azioni in quattro operazioni, generando proventi lordi di circa 73,1 milioni di $. Queste vendite precedenti di maggiore entità corrispondono a circa il 6,5 % delle azioni in circolazione e potrebbero indicare una continua dismissione da parte di un insider chiave.

Poiché il Form 144 è solo una comunicazione d'intento, l'esecuzione non è garantita. Tuttavia, vendite ricorrenti e consistenti da parte di un fondatore o dirigente possono influenzare il sentiment del mercato, soprattutto se non accompagnate da acquisti compensativi o da motivazioni pubbliche.

Sprinklr, Inc. (CXM) – Presentación del Formulario 144 con fecha 29/07/2025

El insider Ragy Thomas ha presentado un Formulario 144 indicando su intención de vender 1.435 acciones ordinarias alrededor del 29 de julio de 2025 a través de Morgan Stanley Smith Barney. Al precio de cierre del 28/07/2025, las acciones tienen un valor de 13.429,73 $. La compañía tiene 142.831.141 acciones en circulación; la venta propuesta representa menos del 0,01 % del total de acciones, por lo que es insignificante en tamaño.

La presentación también revela actividad reciente de insiders: en los últimos tres meses Thomas vendió un total de 9.327.768 acciones en cuatro transacciones, generando ingresos brutos de aproximadamente 73,1 millones de $. Estas ventas anteriores de mayor volumen equivalen a cerca del 6,5 % de las acciones en circulación y podrían indicar una desinversión continua por parte de un insider clave.

Dado que el Formulario 144 es solo un aviso de intención, la ejecución no está garantizada. No obstante, ventas recurrentes y significativas por parte de un fundador o ejecutivo pueden influir en el sentimiento del mercado, especialmente si no se acompañan de compras compensatorias o justificaciones públicas.

Sprinklr, Inc. (CXM) – 2025년 7월 29일자 Form 144 제출

내부자 Ragy Thomas가 Morgan Stanley Smith Barney를 통해 2025년 7월 29일경 1,435주의 보통주를 매도할 의사를 나타내는 Form 144를 제출했습니다. 2025년 7월 28일 종가 기준으로, 해당 주식 가치는 13,429.73달러입니다. 회사의 총 발행 주식 수는 142,831,141주이며, 이번 매도 예정 주식은 총 발행 주식의 0.01% 미만으로 규모가 미미합니다.

이번 제출서에는 최근 내부자 거래 내역도 포함되어 있습니다: 지난 3개월 동안 Thomas는 총 9,327,768주를 4건의 거래로 매도하여 약 7,310만 달러의 총 수익을 올렸습니다. 이와 같은 대규모 이전 매도는 총 발행 주식의 약 6.5%에 해당하며, 주요 내부자의 지속적인 지분 매각 신호일 수 있습니다.

Form 144는 단지 매도 의사 통지일 뿐 실제 거래 실행을 보장하지는 않습니다. 그럼에도 불구하고, 창립자나 경영진의 반복적인 대규모 매도는 보상 매수나 공개적인 설명이 없을 경우 시장 심리에 영향을 줄 수 있습니다.

Sprinklr, Inc. (CXM) – Dépôt du formulaire 144 en date du 29/07/2025

L’initié Ragy Thomas a déposé un formulaire 144 indiquant son intention de vendre 1 435 actions ordinaires aux alentours du 29 juillet 2025 via Morgan Stanley Smith Barney. Au cours de clôture du 28/07/2025, ces actions sont évaluées à 13 429,73 $. La société compte 142 831 141 actions en circulation ; la vente proposée représente donc moins de 0,01 % des actions en circulation et est donc de taille négligeable.

Le dépôt révèle également une activité récente des initiés : au cours des trois derniers mois, Thomas a vendu un total de 9 327 768 actions en quatre transactions, générant un produit brut d’environ 73,1 millions de dollars. Ces ventes précédentes plus importantes représentent environ 6,5 % des actions en circulation et pourraient indiquer une cession continue par un initié clé.

Comme le formulaire 144 n’est qu’un avis d’intention, son exécution n’est pas garantie. Néanmoins, des ventes récurrentes et importantes d’un fondateur ou dirigeant peuvent influencer le sentiment du marché, surtout si elles ne sont pas accompagnées d’achats compensatoires ou d’explications publiques.

Sprinklr, Inc. (CXM) – Form 144 Einreichung vom 29.07.2025

Insider Ragy Thomas hat ein Formular 144 eingereicht, das die Absicht anzeigt, etwa am 29. Juli 2025 über Morgan Stanley Smith Barney 1.435 Stammaktien zu verkaufen. Zum Schlusskurs am 28.07.2025 haben die Aktien einen Wert von 13.429,73 $. Das Unternehmen hat 142.831.141 ausstehende Aktien; der vorgeschlagene Verkauf macht weniger als 0,01 % der ausstehenden Aktien aus und ist somit unerheblich in der Größe.

Die Einreichung offenbart auch kürzliche Insideraktivitäten: In den letzten drei Monaten hat Thomas insgesamt 9.327.768 Aktien in vier Transaktionen verkauft und dabei Bruttoerlöse von etwa 73,1 Millionen $ erzielt. Diese größeren vorherigen Verkäufe entsprechen etwa 6,5 % der ausstehenden Aktien und könnten auf eine fortgesetzte Veräußerung durch einen wichtigen Insider hinweisen.

Da das Formular 144 nur eine Absichtserklärung ist, ist die Ausführung nicht garantiert. Dennoch können wiederkehrende größere Verkäufe eines Gründers oder Führungskraft die Marktstimmung beeinflussen, insbesondere wenn sie nicht durch Ausgleichskäufe oder öffentliche Begründungen begleitet werden.

Positive
  • None.
Negative
  • Founder/insider divested ~9.3 million shares (~6.5 % of O/S) over last 3 months, signalling potential overhang and possible waning insider confidence.
  • Continued Form 144 notice (even if small) reinforces ongoing selling trend.

Insights

TL;DR: Founder has sold ~6.5 % of CXM shares in 3 months; new filing adds a token amount, sentiment mildly negative.

The filing itself covers just 1,435 shares, but the accompanying disclosure of prior sales is the real story. In three large blocks and one smaller trade, Ragy Thomas divested over 9.3 million shares (~6.5 % of outstanding). Such sustained selling by a founder-insider often creates overhang concerns and can pressure valuation multiples, particularly for growth SaaS names like Sprinklr. While sales may stem from diversification or tax needs, the absence of offsetting insider buys limits positive interpretation. I classify the filing as moderately negative but not deeply impactful given Sprinklr’s >140 million-share float and healthy daily liquidity.

Sprinklr, Inc. (CXM) – Comunicazione Form 144 datata 29/07/2025

L'insider Ragy Thomas ha presentato un modulo Form 144 indicando l'intenzione di vendere 1.435 azioni ordinarie intorno al 29 luglio 2025 tramite Morgan Stanley Smith Barney. Al prezzo di chiusura del 28/07/2025, le azioni valgono 13.429,73 $. La società conta 142.831.141 azioni in circolazione; la vendita proposta rappresenta quindi meno dello 0,01 % delle azioni totali ed è pertanto di entità trascurabile.

La comunicazione rivela anche una recente attività degli insider: negli ultimi tre mesi Thomas ha venduto complessivamente 9.327.768 azioni in quattro operazioni, generando proventi lordi di circa 73,1 milioni di $. Queste vendite precedenti di maggiore entità corrispondono a circa il 6,5 % delle azioni in circolazione e potrebbero indicare una continua dismissione da parte di un insider chiave.

Poiché il Form 144 è solo una comunicazione d'intento, l'esecuzione non è garantita. Tuttavia, vendite ricorrenti e consistenti da parte di un fondatore o dirigente possono influenzare il sentiment del mercato, soprattutto se non accompagnate da acquisti compensativi o da motivazioni pubbliche.

Sprinklr, Inc. (CXM) – Presentación del Formulario 144 con fecha 29/07/2025

El insider Ragy Thomas ha presentado un Formulario 144 indicando su intención de vender 1.435 acciones ordinarias alrededor del 29 de julio de 2025 a través de Morgan Stanley Smith Barney. Al precio de cierre del 28/07/2025, las acciones tienen un valor de 13.429,73 $. La compañía tiene 142.831.141 acciones en circulación; la venta propuesta representa menos del 0,01 % del total de acciones, por lo que es insignificante en tamaño.

La presentación también revela actividad reciente de insiders: en los últimos tres meses Thomas vendió un total de 9.327.768 acciones en cuatro transacciones, generando ingresos brutos de aproximadamente 73,1 millones de $. Estas ventas anteriores de mayor volumen equivalen a cerca del 6,5 % de las acciones en circulación y podrían indicar una desinversión continua por parte de un insider clave.

Dado que el Formulario 144 es solo un aviso de intención, la ejecución no está garantizada. No obstante, ventas recurrentes y significativas por parte de un fundador o ejecutivo pueden influir en el sentimiento del mercado, especialmente si no se acompañan de compras compensatorias o justificaciones públicas.

Sprinklr, Inc. (CXM) – 2025년 7월 29일자 Form 144 제출

내부자 Ragy Thomas가 Morgan Stanley Smith Barney를 통해 2025년 7월 29일경 1,435주의 보통주를 매도할 의사를 나타내는 Form 144를 제출했습니다. 2025년 7월 28일 종가 기준으로, 해당 주식 가치는 13,429.73달러입니다. 회사의 총 발행 주식 수는 142,831,141주이며, 이번 매도 예정 주식은 총 발행 주식의 0.01% 미만으로 규모가 미미합니다.

이번 제출서에는 최근 내부자 거래 내역도 포함되어 있습니다: 지난 3개월 동안 Thomas는 총 9,327,768주를 4건의 거래로 매도하여 약 7,310만 달러의 총 수익을 올렸습니다. 이와 같은 대규모 이전 매도는 총 발행 주식의 약 6.5%에 해당하며, 주요 내부자의 지속적인 지분 매각 신호일 수 있습니다.

Form 144는 단지 매도 의사 통지일 뿐 실제 거래 실행을 보장하지는 않습니다. 그럼에도 불구하고, 창립자나 경영진의 반복적인 대규모 매도는 보상 매수나 공개적인 설명이 없을 경우 시장 심리에 영향을 줄 수 있습니다.

Sprinklr, Inc. (CXM) – Dépôt du formulaire 144 en date du 29/07/2025

L’initié Ragy Thomas a déposé un formulaire 144 indiquant son intention de vendre 1 435 actions ordinaires aux alentours du 29 juillet 2025 via Morgan Stanley Smith Barney. Au cours de clôture du 28/07/2025, ces actions sont évaluées à 13 429,73 $. La société compte 142 831 141 actions en circulation ; la vente proposée représente donc moins de 0,01 % des actions en circulation et est donc de taille négligeable.

Le dépôt révèle également une activité récente des initiés : au cours des trois derniers mois, Thomas a vendu un total de 9 327 768 actions en quatre transactions, générant un produit brut d’environ 73,1 millions de dollars. Ces ventes précédentes plus importantes représentent environ 6,5 % des actions en circulation et pourraient indiquer une cession continue par un initié clé.

Comme le formulaire 144 n’est qu’un avis d’intention, son exécution n’est pas garantie. Néanmoins, des ventes récurrentes et importantes d’un fondateur ou dirigeant peuvent influencer le sentiment du marché, surtout si elles ne sont pas accompagnées d’achats compensatoires ou d’explications publiques.

Sprinklr, Inc. (CXM) – Form 144 Einreichung vom 29.07.2025

Insider Ragy Thomas hat ein Formular 144 eingereicht, das die Absicht anzeigt, etwa am 29. Juli 2025 über Morgan Stanley Smith Barney 1.435 Stammaktien zu verkaufen. Zum Schlusskurs am 28.07.2025 haben die Aktien einen Wert von 13.429,73 $. Das Unternehmen hat 142.831.141 ausstehende Aktien; der vorgeschlagene Verkauf macht weniger als 0,01 % der ausstehenden Aktien aus und ist somit unerheblich in der Größe.

Die Einreichung offenbart auch kürzliche Insideraktivitäten: In den letzten drei Monaten hat Thomas insgesamt 9.327.768 Aktien in vier Transaktionen verkauft und dabei Bruttoerlöse von etwa 73,1 Millionen $ erzielt. Diese größeren vorherigen Verkäufe entsprechen etwa 6,5 % der ausstehenden Aktien und könnten auf eine fortgesetzte Veräußerung durch einen wichtigen Insider hinweisen.

Da das Formular 144 nur eine Absichtserklärung ist, ist die Ausführung nicht garantiert. Dennoch können wiederkehrende größere Verkäufe eines Gründers oder Führungskraft die Marktstimmung beeinflussen, insbesondere wenn sie nicht durch Ausgleichskäufe oder öffentliche Begründungen begleitet werden.

false --12-31 0001763950 0001763950 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 24, 2025

 

 

 

Lantern Pharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39318   46-3973463

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

1920 McKinney Avenue, 7th Floor
Dallas, Texas 75201

(Address of principal executive offices)

 

(972) 277-1136

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b)of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock: Par value $0.0001   LTRN   Nasdaq Capital Market

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On July 24, 2025, the Board of Directors (“Board”) of Lantern Pharma Inc. (the “Company”), acting upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Lee T. Schalop, M.D. to the Board. In 2009, Dr. Schalop was a co-founder of Oncoceutics, Inc., a clinical-stage drug discovery and development company, and served in various executive roles at Oncoceutics from 2009 to 2021, including Chief Business Officer from 2009 to 2016, Chief Operating Officer from 2016 to 2020 and Chief Executive Officer from 2020 to January 2021, at which time Oncoceutuics was sold to Chimerix Inc. (NASD: CMRX) for $450 million. Prior to co-founding Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008. Before attending medical school, Dr. Schalop spent more than 19 years in the financial industry at several major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities, including serving as an investment banker from 1985 to 1993 and a research analyst from 1993 to 2004. Dr. Schalop serves on the Supervisory Board of TME Pharma N.V. (Euronext Growth Paris: ALTME), and he served as a Board Observer at Chimerix Inc. until its sale to Jazz Pharmaceuticals in April 2025. He also sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting. Pursuant to the amendment, Section 2.07 of the By-laws was deleted in its entirety and replaced with the following:

 

Section 2.07 Quorum. Unless otherwise provided by law or the Corporation’s Certificate of Incorporation, one-third (33.33%) of the outstanding shares entitled to vote, present in person, by remote communication, if applicable, or represented by proxy, shall constitute a quorum at a meeting of stockholders. Except as otherwise required by law, abstentions and broker non-votes shall be counted to determine whether a quorum is present. In the absence of a quorum, the meeting may be adjourned, from time to time, by the chairman of the meeting or by vote of a majority of the shares so represented without further notice. At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the original meeting. The stockholders present at a meeting may continue to transact business until adjournment, notwithstanding the withdrawal of such number of stockholders as may leave less than a quorum.”

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits Method Filing

 

The following exhibit is filed with this report:

 

Exhibit 3.2

Amendment No. 2 to By-laws of Lantern Pharma Inc.

Filed Electronically herewith

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LANTERN PHARMA INC.
   
Dated: July 29, 2025 /s/ David R. Margrave
  David R. Margrave,
  Chief Financial Officer

 

 

 

 

FAQ

How many Sprinklr (CXM) shares does the Form 144 cover?

1,435 common shares are listed for potential sale on or around 29 Jul 2025.

Who is selling the shares in this Form 144?

The filing cites Ragy Thomas, whose address matches prior insider sale disclosures.

How significant is the new proposed sale relative to shares outstanding?

At under 0.01 % of the 142.8 million shares outstanding, the individual sale is immaterial.

What insider sales occurred in the past three months?

Thomas sold 9,327,768 shares across four trades, raising roughly $73.1 million in gross proceeds.

Does a Form 144 guarantee that the shares will be sold?

No. Form 144 is a notice of intent; the transaction may or may not be executed.
Lantern Pharma Inc

NASDAQ:LTRN

LTRN Rankings

LTRN Latest News

LTRN Latest SEC Filings

LTRN Stock Data

41.74M
9.26M
14.72%
23.34%
2.15%
Biotechnology
Pharmaceutical Preparations
Link
United States
DALLAS